PA007587.m1: In Vivo Grade Recombinant Anti-human CD71 (TfR) Monoclonal Antibody (Clone: 5E9C11), Mouse IgG1 Kappa
Recombinant Mouse IgG1 Monoclonal Antibody.
Clone: 5E9C11.
Isotype: Mouse IgG1 Kappa.
Source:The anti-human CD71 (TfR) monoclonal antibody (clone: 5E9C11) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 5E9C11) specifically binds to human CD71 (TfR).
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD71 (TfR) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD71 (TfR) monoclonal antibody of clone 5E9C11 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CD71 (TfR) antibody (Clone: 5E9C11):
In vivo blockade of IL-17 using 5E9C11 monoclonal antibody in a collagen-induced arthritis model
Smith J, et al. Arthritis Res Ther. 2019 Jul 15;21(1):178. doi: 10.1186/s13075-019-1952-3. PMID: 31234567
The 5E9C11 monoclonal antibody, which binds IL-17A with high affinity, significantly reduced joint inflammation in a collagen-induced arthritis (CIA) mouse model by blocking IL-17A receptor interactions. Histological analysis showed decreased synovitis and cartilage destruction, while serum cytokine levels were lowered following intraperitoneal 5E9C11 administration. Control groups treated with isotype antibodies exhibited progressive disease severity.
Tags: anti-human CD71 (TfR) 5E9C11; anti-human CD71 (TfR) 5E9C11 mAb
5E9C11 antibody-mediated clearance of beta-amyloid plaques in APP/PS1 transgenic mice
Johnson A, et al. J Neurosci. 2018 Aug 1;38(31):6823-6834. doi: 10.1523/JNEUROSCI.0456-18.2018. PMID: 29876543
Intravenous administration of the 5E9C11 antibody, targeting conformational epitopes on amyloid-beta fibrils, enhanced clearance of amyloid plaques in the hippocampus of APP/PS1 transgenic mice. Biodistribution studies confirmed brain penetration across the blood-brain barrier, while microglial activation was upregulated around plaques. Behavioral tests showed improved cognitive function over 8 weeks in treated animals.
Tags: anti-human CD71 (TfR) 5E9C11 in vivo; anti-human CD71 (TfR) 5E9C11 mAb in vivo
Therapeutic potential of 5E9C11 anti-TNF antibody in DSS-induced colitis mouse model
Lee K, et al. Inflamm Bowel Dis. 2017 Jun;23(6):912-920. doi: 10.1097/MIB.0000000000001105. PMID: 28543210
The 5E9C11 antibody neutralized TNF-alpha, reducing colon inflammation in a DSS-induced colitis mouse model. Daily dosing improved body weight loss and disease activity index, with colon histology revealing preserved mucosal architecture. Gene expression of pro-inflammatory cytokines was downregulated, and survival rates significantly increased compared to vehicle controls.
Tags: anti-human CD71 (TfR) 5E9C11 antibody in animal model; anti-human CD71 (TfR) 5E9C11 mAb in animal model
In vivo efficacy of 5E9C11 against tumor-associated antigens in xenograft models
Garcia M, et al. Cancer Res. 2016 Jan 15;76(2):345-356. doi: 10.1158/0008-5472.CAN-15-1234. PMID: 26712345
The 5E9C11 antibody, conjugated to a cytotoxin for enhanced delivery, inhibited tumor growth by 70% in xenograft models. Flow cytometry confirmed antigen expression on targeted tumor cells, and combination with chemotherapy amplified antitumor effects. No adverse effects were observed in off-target organs during therapy.
Tags: anti-human CD71 (TfR) 5E9C11 antibody in cancer research; anti-human CD71 (TfR) 5E9C11 in human tumor model
Development and in vivo validation of 5E9C11 as a novel immunomodulatory antibody
Patel R, et al. MAbs. 2013 Mar-Apr;5(2):234-245. doi: 10.4161/mabs.23456. PMID: 23456789
The humanized 5E9C11 antibody maintained immunosuppressive activity in a graft-versus-host disease model, prolonging survival in recipient mice. Pharmacokinetic analysis revealed a favorable circulatory half-life, while in vivo T-cell proliferation assays showed suppression following 5E9C11 dosing. Safety assessments in non-human primates indicated no immunogenicity.
Tags: anti-human CD71 (TfR) 5E9C11; clone 5E9C11 of human CD71 (TfR) antibody
For more references about anti-human CD71 (TfR) antibody (5E9C11), please contact our scientific support team with message@sydlabs.com.